Short Interest in Apollomics, Inc. (NASDAQ:APLM) Increases By 737.9%

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 24,300 shares, an increase of 737.9% from the November 15th total of 2,900 shares. Based on an average daily volume of 298,400 shares, the short-interest ratio is currently 0.1 days. Approximately 3.6% of the company’s stock are sold short.

Apollomics Stock Up 0.5 %

Shares of APLM stock opened at $7.74 on Friday. Apollomics has a fifty-two week low of $6.50 and a fifty-two week high of $105.00. The stock’s 50-day moving average is $11.82 and its two-hundred day moving average is $15.79.

Hedge Funds Weigh In On Apollomics

A hedge fund recently raised its stake in Apollomics stock. George Kaiser Family Foundation grew its holdings in shares of Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the quarter. Apollomics comprises about 0.0% of George Kaiser Family Foundation’s investment portfolio, making the stock its 18th biggest position. George Kaiser Family Foundation owned approximately 0.75% of Apollomics worth $141,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.